291
Participants
Start Date
December 7, 2020
Primary Completion Date
April 28, 2022
Study Completion Date
April 28, 2022
Dulaglutide
Administered SC
Placebo
Administered SC
Insulin Glargine
Administered SC
Beijing Pinggu District Hospital, Beijing
Dalian Municipal Central Hospital Affiliated of Dalian Medical University, Dalian
The First Hospital of Jilin University, Changchun
First Affiliated Hospital of the Harbin Medical University, Harbin
The Fourth Affiliated Hospital of Harbin Medical University, Harbin
Shanghai Putuo District Center Hospital, Shanghai
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School, Nanjing
The Second Affiliated Hospital of Nanjing Medical University, Nanjing
The First Hospital of Nanjing, Nanjing
Nanjing Medical University - Nanjing Jiangning Hospital, Nanjing
Changzhou No.2 People's Hospital, Changzhou
Wuxi People's Hospital, Wuxi
The Affiliated Jiangyin Hospital of Southeast University Medical College, Wuxi
No. 2 Affiliated Hospital of Suzhou University, Suzhou
The Second People's Hospital of Hefei, Hefei
Jinan Central Hospital, Jinan
Tianjin Medical University General Hospital, Tianjin
Zhejiang Hospital, Hangzhou
The Third Hospital of Nanchang, Nanchang
Pingxiang People's Hospital, Pingxiang
Chongqing General Hospital, Chongqing
The Second Affiliated Hospital of Zhengzhou University, Zhengzhou
The First Affiliated Hospital of Henan University of Science &Technology, Luoyang Shi
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou
West China Hospital Sichuan University, Chengdu
The First People's Hospital of Yunnan Province, Kunming
The First Affiliated Hospital of Xi'an Medical University, Xi’an
Eli Lilly and Company
INDUSTRY